IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Tonby, Kristian ^a,b   Ruhwald, Morten ^c   Kvale, Dag ^a,b   Dyrhol Riise, Anne Ma ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CXCL10 PROTEIN, HUMAN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; TUBERCULOSTATIC AGENT;

ADULT; AGED; BLOOD; COHORT ANALYSIS; DRIED BLOOD SPOT TESTING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; TUBERCULOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BIOMARKERS; CHEMOKINE CXCL10; COHORT STUDIES; DRIED BLOOD SPOT TESTING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84924939688     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09223     Document Type: Article

References (47)

1. World health organization. Global Tuberculosis report 2014. Available at: http://www.who.int/tb/publications/global-report/en/. (Accessed 12 December 2014).
2. Wallis, R. S. et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect. Dis. 13, 362-372 (2013).
3. Gandhi, N. R. et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375, 1830-1843 (2010).
4. Lange, C. et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur. Respir. J. 44, 23-63 (2014).
5. Heyckendorf, J., Olaru, I. D., Ruhwald, M. & Lange, C. Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 190, 374-383 (2014).
6. Chegou, N. N., Heyckendorf, J., Walzl, G., Lange, C. & Ruhwald, M. Beyond the IFN-gamma horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. Eur. Respir. J. 43, 1472-1486 (2014).
7. Liu, M. et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 22, 121-130 (2011).
8. Ruhwald, M., Aabye, M. G. & Ravn, P. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. Expert Rev. Mol. Diagn. 12, 175-187 (2012).
9. den Hertog, A. L., de Vos, A. F., Klatser, P. R. & Anthony, R. M. Early specific host response associated with starting effective tuberculosis treatment in an infection controlled placebo controlled mouse study. PLoS One 8, e57997 (2013).
10. de Steenwinkel, J. E. et al. Dynamics of interferon-gamma release assay and cytokine profiles in blood and respiratory tract specimens from mice with tuberculosis and the effect of therapy. Eur. J. Clin. Microbiol. Infect. Dis 31, 1195-1201 (2012).
11. Cannas, A. et al. IP-10 detection in urine is associated with lung diseases. BMC Infect. Dis. 10, 333 (2010).
12. Azzurri, A. et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes. Infect. 7, 1-8 (2005).
13. Su, W. L. et al. Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. Clin. Vaccine Immunol. 17, 223-231 (2010).
14. Riou, C. et al. Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis. PLoS One 7, e36886 (2012).
15. Mihret, A. et al. Plasma cytokines and chemokines differentiate between active disease and non-active tuberculosis infection. J. Infect. 66, 357-365 (2013).
16. Kabeer, B. S. et al. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect. Dis. 11, 135 (2011).
17. Hong, J. Y. et al. Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment. J. Infect. 68, 252-258 (2014).
18. Dheda, K., Ruhwald, M., Theron, G., Peter, J. & Yam, W. C. Point-of-care diagnosis of tuberculosis: Past, present and future. Respirology 18, 217-232 (2013).
19. Johannessen, A. Dried blood spots in HIV monitoring: applications in resource-limited settings. Bioanalysis 2, 1893-1908 (2010).
20. Brantsaeter, A. B. et al. Cytomegalovirus viremia in dried blood spots is associated with an increased risk of death in HIV-infected patients: a cohort study from rural Tanzania. Int. J. Infect. Dis. 16, e879-885 (2012).
21. Syed Ahamed Kabeer, B., Raman, B., Thomas, A., Perumal, V. & Raja, A. Role of QuantiFERON-TB gold, interferon gamma inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS One 5, e9051 (2010).
22. Frahm, M. et al. Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis (Edinb) 91, 250-256 (2011).
23. Essone, P. N. et al. Host Cytokine Responses Induced after Overnight Stimulation with Novel M. tuberculosis Infection Phase-Dependent Antigens Show Promise as Diagnostic Candidates for TB Disease. PLoS One 9, e102584 (2014).
24. Borgstrom, E. et al. Immune responses to ESAT-6 and CFP-10 by FASCIA and multiplex technology for diagnosis of M. tuberculosis infection; IP-10 is a promising marker. PLoS One 7, e43438 (2012).
25. Ruhwald, M. et al. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb) 91, 260-267 (2011).
26. Goletti, D. et al. IFN-gamma, but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. J. Infect. 61, 133-143 (2010).
27. Dheda, K. et al. Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting. PLoS One 4, e4689 (2009).
28. Sutherland, J. S. et al. Highly accurate diagnosis of pleural tuberculosis by immunological analysis of the pleural effusion. PLoS One 7, e30324 (2012).
29. Fu, X., Yang, B., Lao, S., Fan, Y. & Wu, C. Human memory-like NK cells migrating to tuberculous pleural fluid via IP-10/CXCR3 and SDF-1/CXCR4 axis produce IFN-gamma in response to Bacille Calmette Guerin. Clin. Immunol. 148, 113-123 (2013).
30. Nolan, A. et al. Elevated IP-10 and IL-6 from bronchoalveolar lavage cells are biomarkers of non-cavitary tuberculosis. Int. J. Tuberc. Lung Dis. 17, 922-927 (2013).
31. Ruhwald, M. et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur. Respir. J. 32, 1607-1615 (2008).
32. Vanini, V. et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J. Infect. 65, 49-59 (2012).
33. Goletti, D. et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS One 5, e12577 (2010).
34. Whittaker, E., Gordon, A. & Kampmann, B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma? PLoS One 3, e3901 (2008).
35. Ruhwald, M. et al. Improving T-cell assays for the diagnosis of latent TB infection: potential of a diagnostic test based on IP-10. PLoS One 3, e2858 (2008).
36. Alsleben, N. et al. Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: a case-control study. Scand. J. Infect. Dis. 44, 256-262 (2012).
37. Beinhardt, S. et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 142, 78-85. e72 (2012).
38. Askarieh, G. et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 51, 1523-1530 (2010).
39. Lawn, S. D. & Zumla, A. I. Tuberculosis. Lancet 378, 57-72 (2011).
40. Horne, D. J. et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect. Dis. 10, 387-394 (2010).
41. Aabye, M. G. et al. A simplemethod to quantitate IP-10 in dried blood and plasma spots. PLoS One 7, e39228 (2012).
42. Aabye, M. G. et al. Dried plasma spots in the diagnosis of tuberculosis: IP-10 release assay on filter paper. Eur. Respir. J. 42, 495-503 (2013).
43. Bobosha, K. et al. Field-Evaluation of a New Lateral Flow Assay for Detection of Cellular and Humoral Immunity against Mycobacterium leprae. PLoS Negl. Trop. Dis. 8, e2845 (2014).
44. Noel, N. et al. Elevated IP10 levels are associated with immune activation and low CD4(+) T-cell counts in HIV controller patients. AIDS 28, 467-476 (2014).
45. Geyer, A. I. et al. Plasma level of interferon gamma induced protein 10 is amarker of sarcoidosis disease activity. Cytokine 64, 152-157 (2013).
46. Chen, Y. C. et al. Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis. Disease markers 31, 101-110 (2011).
47. Drabe, C. H., Blauenfeldt, T. & Ruhwald, M. ELISA-based assay for IP-10 detection from filter paper samples. Methods Mol. Biol. 1172, 27-37 (2014).